Advertisement

Newly Recognized Forms of Prostate-Specific Antigen and Emerging Molecular Markers

  • Eduardo I. Canto
  • Kevin M. Slawin
Part of the Current Clinical Urology book series (CCU)

Abstract

Total PSA has been the mainstay of diagnostic laboratory investigation for prostate cancer. However, a number of isoforms of this molecule and other emerging markers offer the promise of improved diagnostic strategies.

Keywords

prostate specific antigen (PSA) molecular forms of free PSA prostate cancer screening MALDI-TOF SELDI-TOF 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Lilja H. Biology of prostate-specific antigen. Urology 2003;62(5 Suppl 1):27–33.CrossRefPubMedGoogle Scholar
  2. 2.
    Diamandis EP. Prostate specific antigen—new applications in breast and other cancers. Anticancer Res 1996;16(6C):3983–3984.PubMedGoogle Scholar
  3. 3.
    Olsson AY, Bjartell A, Lilja H, Lundwall A. Expression of prostate-specific antigen (PSA) and human glandular kallikrein 2 (hK2) in ileum and other extraprostatic tissues. Int J Cancer 2005;113(2):290–297.CrossRefPubMedGoogle Scholar
  4. 4.
    Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostatespecific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317(15):909–916.PubMedCrossRefGoogle Scholar
  5. 5.
    Bunting PS. A guide to the interpretation of serum prostate specific antigen levels. Clin Biochem 1995;28(3):221–241.CrossRefPubMedGoogle Scholar
  6. 6.
    Hara M, Inorre T, Fukuama T. Some physico-chemical characteristics of gamma-seminoprotein, an antigenic component specific for human seminal plasma. Jpn J Leg Med 1971;25:322.Google Scholar
  7. 7.
    Ablin RJ, Soanes WA, Bronson P, Witebsky E. Precipitating antigens of the normal human prostate. J Reprod Fertil 1970;22(3):573–574.PubMedGoogle Scholar
  8. 8.
    Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest Urol 1979;17(2):159–163.PubMedGoogle Scholar
  9. 9.
    Papsidero LD, Wang MC, Valenzuela LA, Murphy GP, Chu TM. A prostate antigen in sera of prostatic cancer patients. Cancer Res 1980;40(7):2428–2432.PubMedGoogle Scholar
  10. 10.
    Christensson A, Laurell CB, Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 1990;194(3):755–763.CrossRefPubMedGoogle Scholar
  11. 11.
    Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51(1):222–226.PubMedGoogle Scholar
  12. 12.
    Lilja H. Regulation of the enzymatic activity of prostate-specific antigen and its reactions with extracellular protease inhibitors in prostate cancer. Scand J Clin Lab Invest Suppl 1995;220:47–56.PubMedGoogle Scholar
  13. 13.
    Zhang WM, Leinonen J, Kalkkinen N, Stenman UH. Prostate-specific antigen forms a complex with and cleaves alpha 1-protease inhibitor in vitro. Prostate 1997;33(2):87–96.CrossRefPubMedGoogle Scholar
  14. 14.
    Zhou Z, Armstrong EG, Belenky A, Freeman JV, Yeung KK. Equivalent recognition of free and ACT-complexed PSA in a monoclonal-polyclonal sandwich assay is conferred by binding specificity of the monoclonal antibody. J Clin Lab Anal 1998;12(4):242–249.CrossRefPubMedGoogle Scholar
  15. 15.
    Junker R, Brandt B, Zechel C, Assmann G. Comparison of prostate-specific antigen (PSA) measured by four combinations of free PSA and total PSA assays. Clin Chem 1997;43(9):1588–1594.PubMedGoogle Scholar
  16. 16.
    Nixon RG, Meyer GE, Blase AB, Gold MH, Brawer MK. Comparison of 3 investigational assays for the free form of prostate specific antigen. J Urol 1998;160(2):420–425.CrossRefPubMedGoogle Scholar
  17. 17.
    Catalona WJ, Partin AW, Slawin KM, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998;279(19):1542–1547.CrossRefPubMedGoogle Scholar
  18. 18.
    Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995;273(4):289–294.CrossRefPubMedGoogle Scholar
  19. 19.
    Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 1997;277(18):1452–1455.CrossRefPubMedGoogle Scholar
  20. 20.
    Vashi AR, Wojno KJ, Henricks W, et al. Determination of the “reflex range” and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system. Urology 1997;49(1):19–27.CrossRefPubMedGoogle Scholar
  21. 21.
    Partin AW, Brawer MK, Bartsch G, et al. Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. J Urol 2003;170(5):1787–1791.CrossRefPubMedGoogle Scholar
  22. 22.
    Djavan B, Remzi M, Zlotta AR, et al. Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial. Urology 2002;60(4 Suppl 1):4–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Catalona WJ, Bartsch G, Rittenhouse HG, et al. Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. J Urol 2003;170(6 Pt 1):2181–2185.CrossRefPubMedGoogle Scholar
  24. 24.
    Canto EI, Singh H, Shariat SF, et al. Effects of systematic 12-core biopsy on the performance of percent free prostate specific antigen for prostate cancer detection. J Urol 2004;172(3):900–904.CrossRefPubMedGoogle Scholar
  25. 25.
    Roddam AW, Duffy MJ, Hamdy FC, et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2–10 ng/ml: systematic review and meta-analysis. Eur Urol 2005;48(3):386–399; discussion 98–9.PubMedGoogle Scholar
  26. 26.
    Meyer A, Jung K, Lein M, Rudolph B, Schnorr D, Loening SA. Factors influencing the ratio of free to total prostate-specific antigen in serum. Int J Cancer 1997;74(6):630–636.CrossRefPubMedGoogle Scholar
  27. 27.
    Arcangeli CG, Smith DS, Ratliff TL, Catalona WJ. Stability of serum total and free prostate specific antigen under varying storage intervals and temperatures. J Urol 1997;158(6):2182–2187.CrossRefPubMedGoogle Scholar
  28. 28.
    Lynn NN, Collins GN, O’Reilly PH. Prostatic manipulation has a minimal effect on complexed prostate-specific antigen levels. BJU Int 2000;86(1):65–67.CrossRefPubMedGoogle Scholar
  29. 29.
    Denmeade SR, Lovgren J, Khan SR, Lilja H, Isaacs JT. Activation of latent protease function of pro-hK2, but not pro-PSA, involves autoprocessing. Prostate 2001;48(2):122–126.CrossRefPubMedGoogle Scholar
  30. 30.
    Takayama TK, Carter CA, Deng T. Activation of prostate-specific antigen precursor (pro-PSA) by prostin, a novel human prostatic serine protease identified by degenerate PCR. Biochemistry 2001;40(6):1679–1687.CrossRefPubMedGoogle Scholar
  31. 31.
    Nelson PS, Gan L, Ferguson C, et al. Molecular cloning and characterization of prostase, an androgen-regulated serine protease with prostate-restricted expression. Proc Natl Acad Sci USA 1999;96(6):3114–3119.CrossRefPubMedGoogle Scholar
  32. 32.
    Lovgren J, Rajakoski K, Karp M, Lundwall A, Lilja H. Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. Biochem Biophys Res Commun 1997;238(2):549–555.CrossRefPubMedGoogle Scholar
  33. 33.
    Zhang WM, Leinonen J, Kalkkinen N, Dowell B, Stenman UH. Purification and characterization of different molecular forms of prostate-specific antigen in human seminal fluid. Clin Chem 1995;41(11):1567–1573.PubMedGoogle Scholar
  34. 34.
    Chen Z, Chen H, Stamey TA. Prostate specific antigen in benign prostatic hyperplasia: purification and characterization. J Urol 1997;157(6):2166–2170.CrossRefPubMedGoogle Scholar
  35. 35.
    Mikolajczyk SD, Millar LS, Wang TJ, et al. “BPSA,” a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. Urology 2000;55(1):41–45.CrossRefPubMedGoogle Scholar
  36. 36.
    Wang TJ, Slawin KM, Rittenhouse HG, Millar LS, Mikolajczyk SD. Benign prostatic hyperplasia-associated prostate-specific antigen (BPSA) shows unique immunoreactivity with anti-PSA monoclonal antibodies. Eur J Biochem 2000;267(13):4040–4045.CrossRefPubMedGoogle Scholar
  37. 37.
    Canto EI, Singh H, Shariat SF, et al. Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer. Urology 2004;63(5):905–910; discussion 10–11.CrossRefPubMedGoogle Scholar
  38. 38.
    Morote J, Encabo G, Lopez M, de Torres IM. Prediction of prostate volume based on total and free serum prostate-specific antigen: is it reliable? Eur Urol 2000;38(1):91–95.CrossRefPubMedGoogle Scholar
  39. 39.
    Linton HJ, Marks LS, Millar LS, Knott CL, Rittenhouse HG, Mikolajczyk SD. Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate disease. Clin Chem 2003;49(2):253–259.CrossRefPubMedGoogle Scholar
  40. 40.
    Slawin KM, Levitt JM, Roehrborn CG, et al. The relationship between PSA isoforms and BPH-related prostate volume at baseline in the MTOPS trial. Presented at the 101st American Urological Association Annual Meeting, 2006.Google Scholar
  41. 41.
    Slawin KM, Levitt JM, Lamb DJ, et al. Prediction of prostate volume using molecular forms of PSA in men with BPH enrolled on the GSK phase III dutasteride trials. Presented at the 101st American Urological Association Annual Meeting, 2006.Google Scholar
  42. 42.
    Slawin KM, Levitt JM, Lamb DJ, et al. Baseline serum BPH-A level enhances the accuracy of a nomogram to predict BPH progression in men enrolled on the GSK phase III dutasteride trials. Presented at the 101st American Urological Association Annual Meeting, 2006.Google Scholar
  43. 43.
    Kurkela R, Herrala A, Henttu P, Nai H, Vihko P. Expression of active, secreted human prostate-specific antigen by recombinant baculovirus-infected insect cells on a pilot-scale. Biotechnology (NY) 1995;13(11):1230–1234.CrossRefGoogle Scholar
  44. 44.
    Kumar A, Mikolajczyk SD, Goel AS, Millar LS, Saedi MS. Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2. Cancer Res 1997;57(15):3111–3114.PubMedGoogle Scholar
  45. 45.
    Mikolajczyk SD, Grauer LS, Millar LS, et al. A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. Urology 1997;50(5):710–714.CrossRefPubMedGoogle Scholar
  46. 46.
    Kumar A, Mikolajczyk SD, Hill TM, Millar LS, Saedi MS. Different proportions of various prostate-specific antigen (PSA) and human kallikrein 2 (hK2) forms are present in noninduced and androgen-induced LNCaP cells. Prostate 2000;44(3):248–254.CrossRefPubMedGoogle Scholar
  47. 47.
    Noldus J, Chen Z, Stamey TA. Isolation and characterization of free form prostate specific antigen (f-PSA) in sera of men with prostate cancer. J Urol 1997;158(4):1606–1609.CrossRefPubMedGoogle Scholar
  48. 48.
    Mikolajczyk SD, Marker KM, Millar LS, et al. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res 2001;61(18):6958–6963.PubMedGoogle Scholar
  49. 49.
    Mikolajczyk SD, Millar LS, Wang TJ, et al. A precursor form of prostatespecific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. Cancer Res 2000;60(3):756–759.PubMedGoogle Scholar
  50. 50.
    Mikolajczyk SD, Catalona WJ, Evans CL, et al. Proenzyme forms of prostatespecific antigen in serum improve the detection of prostate cancer. Clin Chem 2004;50(6):1017–2105.CrossRefPubMedGoogle Scholar
  51. 51.
    Steuber T, Nurmikko P, Haese A, et al. Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen. J Urol 2002;168(5):1917–1922.CrossRefPubMedGoogle Scholar
  52. 52.
    Niemela P, Lovgren J, Karp M, Lilja H, Pettersson K. Sensitive and specific enzymatic assay for the determination of precursor forms of prostate-specific antigen after an activation step. Clin Chem 2002;48(8):1257–1264.PubMedGoogle Scholar
  53. 53.
    Petricoin EE, Paweletz CP, Liotta LA. Clinical applications of proteomics: proteomic pattern diagnostics. J Mammary Gland Biol Neoplasia 2002;7(4):433–440.CrossRefPubMedGoogle Scholar
  54. 54.
    Qu Y, Adam BL, Yasui Y, et al. Boosted decision tree analysis of surfaceenhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin Chem 2002;48(10):1835–1843.PubMedGoogle Scholar
  55. 55.
    Adam BL, Qu Y, Davis JW, et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002;62(13):3609–3664.PubMedGoogle Scholar
  56. 56.
    Petricoin EF 3rd, Ornstein DK, Paweletz CP, et al. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 2002;94(20):1576–1678.PubMedGoogle Scholar
  57. 57.
    Zheng Y, Xu Y, Ye B, et al. Prostate carcinoma tissue proteomics for biomarker discovery. Cancer 2003;98(12):2576–2582.CrossRefPubMedGoogle Scholar

Copyright information

© Humana Press, a part of Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Eduardo I. Canto
    • 1
    • 2
  • Kevin M. Slawin
    • 1
    • 2
  1. 1.Antilles Research InstituteSan JuanPR
  2. 2.Baylor Prostate Center, Scott Department of UrologyBaylor College of MedicineHouston

Personalised recommendations